Regeneron Pharmaceuticals Inc
(BSP:REGN34)
R$
89.25
1.25 (1.42%)
Market Cap: 590.31 Bil
Enterprise Value: 549.72 Bil
PE Ratio: 24.59
PB Ratio: 3.63
GF Score: 86/100 Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 12, 2020 / 12:20PM GMT
Release Date Price:
R$55.85
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay, everyone, good morning. Welcome to the virtual Vegas conference at Bank of America. This is our first session this morning. We're really happy to have Regeneron this morning presenting. Speaking on behalf of Regeneron is Marion McCourt, who is Senior Vice President and Head of Commercial. Marion, you there?
Marion E. McCourt
Regeneron Pharmaceuticals, Inc. - SVP of Commercial
I am, Geoff, and hello to everybody. Pleasure to join you today.
Questions & Answers
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay. Great. So we'll do a Q&A here with the team, and there is an ability to ask a question online as well, if listeners want to do that.
So Marion, let's talk post the first quarter. So it looked like EYLEA sales held up probably a bit better than people thought in the first quarter. Looking to 2Q, what's your expectation for the persistency rates in the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot